Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Inflammatory Bowel Diseases

Free Subscription Articles published in Lancet Retrieve available abstracts of 18 articles: HTML format

Single Articles

March 2024
1. NIELSEN OH, Gubatan JM, Kolho KL, Streett SE, et al
   Updates on the management of inflammatory bowel disease from periconception to pregnancy and lactation.
   Lancet. 2024 Mar 5:S0140-6736(24)00052-7. doi: 10.1016/S0140-6736(24)00052.
   PubMed     Abstract available
   
   
   
2. DOLINGER M, Torres J, Vermeire S
   Crohn's disease.
   Lancet. 2024 Mar 1:S0140-6736(23)02586-2. doi: 10.1016/S0140-6736(23)02586.
   PubMed     Abstract available
   
   
   August 2023
3. LE BERRE C, Honap S, Peyrin-Biroulet L
   Ulcerative colitis.
   Lancet. 2023;402:571-584.
   PubMed     Abstract available
   
   
   March 2023
4. SANDBORN WJ, Vermeire S, Peyrin-Biroulet L, Dubinsky MC, et al
   Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies.
   Lancet. 2023 Mar 2:S0140-6736(23)00061-2. doi: 10.1016/S0140-6736(23)00061.
   PubMed     Abstract available
   
   
   
5. ATREYA R, Neurath MF
   The sphingosine-1-phosphate receptor agonist etrasimod in ulcerative colitis.
   Lancet. 2023 Mar 2:S0140-6736(23)00228-3. doi: 10.1016/S0140-6736(23)00228.
   PubMed    
   
   
   June 2022
6. SANDS BE, Irving PM, Hoops T, Izanec JL, et al
   Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial.
   Lancet. 2022;399:2200-2211.
   PubMed     Abstract available
   
   
   
7. CHAPMAN TP, Satsangi J
   Head-to-head biologic therapy in Crohn's disease.
   Lancet. 2022;399:2169-2171.
   PubMed    
   
   
   
8. BANARES J, Aceituno L, Jimenez A, Maynard A, et al
   Sweet's syndrome and Crohn's disease diagnosed simultaneously.
   Lancet. 2022;399:2155.
   PubMed    
   
   
   May 2022
9. FERRANTE M, Panaccione R, Baert F, Bossuyt P, et al
   Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial.
   Lancet. 2022;399:2031-2046.
   PubMed     Abstract available
   
   
   
10. D'HAENS G, Panaccione R, Baert F, Bossuyt P, et al
    Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials.
    Lancet. 2022;399:2015-2030.
    PubMed     Abstract available
    
    
    
11. HIBI T
    Risankizumab for Crohn's disease.
    Lancet. 2022;399:1992-1993.
    PubMed    
    
    
    
12. DANESE S, Vermeire S, Zhou W, Pangan AL, et al
    Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials.
    Lancet. 2022 May 26. pii: S0140-6736(22)00581.
    PubMed     Abstract available
    
    
    
13. ANANTHAKRISHNAN AN
    Upadacitinib for ulcerative colitis.
    Lancet. 2022 May 26. pii: S0140-6736(22)00778.
    PubMed    
    
    
    August 2021
14. MCLORNAN DP, Pope JE, Gotlib J, Harrison CN, et al
    Current and future status of JAK inhibitors.
    Lancet. 2021;398:803-816.
    PubMed     Abstract available
    
    
    July 2021
15. RAMSPOTT JP, Neureiter D, Emmanuel K, Jager T, et al
    Granulomatosis with polyangiitis presents with skip lesions of the bowel.
    Lancet. 2021;398:e8.
    PubMed    
    
    
    
16. SMERAT T, Khdour M, Abdoh Q, Hallak H, et al
    Assessment of health-related quality of life in patients with inflammatory bowel disease in occupied Palestinian territory: a correlation cross-sectional study.
    Lancet. 2021;398 Suppl 1:S48.
    PubMed     Abstract available
    
    
    June 2021
17. HOLMER AK, Singh S
    Expanding targeted immune modulators in ulcerative colitis.
    Lancet. 2021 Jun 3. pii: S0140-6736(21)00891.
    PubMed    
    
    
    
18. FEAGAN BG, Danese S, Loftus EV Jr, Vermeire S, et al
    Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trial.
    Lancet. 2021 Jun 3. pii: S0140-6736(21)00666.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Inflammatory Bowel Diseases is free of charge.